Drug-labels.com

Idvynso: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
100 mg / 0.25 mg
Active ingredients:

Source: Health Canada – Drug Product Database (DPD) and product monographs · About this document

Patient Medication Information: uses, side effects, how to take - Idvynso

What IDVYNSO® is used for:

IDVYNSO® is used to treat adults living with HIV to replace their current HIV-1.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

How IDVYNSO® works:

IDVYNSO® contains two medications, doravirine and islatravir. These medicines work together to reduce the amount of HIV-1 in your body and keep it at a low level.

This helps maintain the number of CD4+ T-cell count in your blood. CD4+ T-cells are a type of white blood cells that are important in helping your body to fight infection.

IDVYNSO® does not cure HIV infection.

The ingredients in IDVYNSO® are:

Medicinal ingredients: doravirine and islatravir.

Non-medicinal ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The film coating material contains the following inactive ingredients: calcium carbonate, ferric oxide, ferrosoferric oxide, hypromellose, lactose monohydrate, triacetin. The coated tablets are polished with carnauba wax.

IDVYNSO® comes in the following dosage form:

IDVYNSO® is available as a pink, oval-shaped, film-coated tablet, and is debossed with 772 on one side and plain on the other side. Each tablet contains 100 mg of doravirine and 0.25 mg of islatravir.

Do not use IDVYNSO® if:

  • You are allergic to any ingedient in IDVYNSO® or to any component of the container.

  • You are taking any of the following drugs that may decrease the effectiveness of IDVYNSO®:

    • carbamazepine, oxcarbazepine, phenobarbital, and phenytoin, medicines used to treat seizures
    • enzalutamide, a medicine used to treat prostate cancer
    • rifampin, a medicine used to treat tuberculosis
    • mitotane, a medicine used to treat certain cancers
    • St. John’s wort (Hypericum perforatum)
    • lamivudine or emtricitabine, medicines used to treat HIV-1 infection

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take IDVYNSO®. Talk about any health conditions or problems you may have, including if you:

  • have kidney problems
  • have liver problems
  • have had hepatitis B virus infection

Other warnings you should know about:

Blood Sugar and Fat Levels: Your blood sugar levels (glucose) or levels of fats (lipids) in your blood may increase with HIV treatment. Your doctor may order blood tests for you.

Pregnancy

Tell your healthcare professional if you are pregnant or plan to get pregnant.

  • It is not known if IDVYNSO® could harm your baby while you are pregnant.
  • If you are taking HIV medicines and you are pregnant, talk to your doctor about the Antiretroviral Pregnancy Registry. The Registry collects information about mothers and their babies if the mother takes HIV medicines during pregnancy.

Breastfeeding

Tell your healthcare professional if you are breastfeeding or plan to breastfeed. Do not breastfeed while you are taking IDVYNSO®. It is not known if IDVYNSO® passes into your breast milk. The following risks to your baby from breastfeeding during treatment with IDVYNSO® include:

  • the HIV-1 virus may pass to your baby if your baby does not have HIV-1 infection.
  • the HIV-1 virus may become harder to treat if your baby has HIV-1 infection.
  • your baby may get side effects from IDVYNSO®.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with IDVYNSO®:

  • cladribine – used to treat multiple sclerosis.
  • clofarabine – used to treat leukemia (cancer).
  • cytarabine - used to treat leukemia (cancer).
  • gemcitabine – used to treat various forms of cancer
  • pentostatin – used to treat leukemia (cancer).

If IDVYNSO® is taken with rifabutin, take one tablet of doravirine (PIFELTRO®) approximately 12 hours after the dose of IDVYNSO®. Your healthcare professional will tell you what to do.

How to take IDVYNSO®:

  • Take IDVYNSO® every day exactly as your healthcare professional tells you to take it.

  • Do not change your dose or stop taking IDVYNSO® without talking to your healthcare professional. Stay under a doctor’s care when taking IDVYNSO®. When your IDVYNSO® supply

    • starts to run low, get more from your doctor or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to IDVYNSO® and become harder to treat.
  • IDVYNSO® is taken by itself (not with other HIV-1 medicines) to treat HIV-1 infection. Swallow tablet whole, do not divide, crush or chew.

  • IDVYNSO® can be taken with or without food.

Usual dose:

  • Take 1 IDVYNSO® tablet by mouth each day, at about the same time every day.

Overdose:

If you think you, or a person you are caring for, have taken too much IDVYNSO®, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

It is important that you do not miss or skip doses of IDVYNSO®.

  • If you miss a dose of IDVYNSO® within 12 hours of the time you usually take it, take your dose as soon as you remember. Then take your next dose of IDVYNSO® at your regular time.
  • If you miss a dose of IDVYNSO® by more than 12 hours of the time you usually take it, skip the missed dose and take the next dose of IDVYNSO® at your regular time.
  • Do not take 2 doses of IDVYNSO® at the same time.

Possible side effects from using IDVYNSO®:

These are not all the possible side effects you may have when taking IDVYNSO®. If you experience any side effects not listed here, tell your healthcare professional.

The most common side effects of IDVYNSO® in adults are:

  • diarrhea
  • headache
  • abdominal bloating
  • dizziness
  • fatigue

Serious side effects and what to do about them

Frequency/Side Effect/SymptomTalk to your healthcare professionalStop taking this drug and get immediate medical help
Frequency/Side Effect/SymptomTalk to your healthcare professionalStop taking this drug and get immediate medical help
Only if severeIn all cases
Only if severeIn all cases
Unknown
Severe skin reactions: fever, severe rash, swollen lymph glands, flu-like feeling, blisters and peeling skin that may start in and around the mouth, nose, eyes and genitals and spread to other areas of the
√
body, yellow skin or eyes, shortness of breath, chest pain or discomfort, urinating less often, less urine

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store IDVYNSO® in the original bottle. Keep the bottle tightly closed to protect from moisture. Do not remove the desiccant.

Store IDVYNSO® at room temperature (15°C to 30°C).

Keep out of reach and sight of children.

If you want more information about IDVYNSO®:

  • Talk to your healthcare professional.
  • Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website www.merck.ca; or by calling 1-800-567-2594.

Date of Authorization: 2026-06-03

® Merck Sharp & Dohme LLC. Used under license.

© 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02568748

Approved according to the text: June 3, 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Idvynso

Rx or OTC
Prescription (Rx)?
DIN 02568748
Schedule(s) PRESCRIPTION
Active ingredient(s) Doravirine 100 MG, Islatravir 0.25 MG
Dosage form(s) Tablet
Route(s) of administration Oral
Company MERCK CANADA INC
Current status Approved
Current status date June 3, 2026

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.